长期服用抗精神病药的慢性精神分裂症患者血清S100B蛋白浓度变化  

Increased serum S100B protein in long-term antipsychotic medication chronic patients with schizophrenia

作　　者：谭云龙[1] 谭淑平[1] 陈楠[1] 韩标[1] 杨甫德[1] 曹连元[1] 李佳[1] 周东丰[2] 邹义壮[1] 

机构地区：[1]北京回龙观医院精神医学研究中心,北京100096 [2]北京大学精神卫生研究所,卫生部精神卫生学重点实验室(北京大学),北京100191

出　　处：《中国心理卫生杂志》2010年第4期261-264,共4页Chinese Mental Health Journal

基　　金：北京市科委重大项目(D0906001000091);北京市优秀人才培养(20061D0301400098)

摘　　要：目的:探讨血清S100B蛋白浓度在长期服用抗精神病药慢性精神分裂症患者中的变化及与精神病理症状间的关系。方法:采用酶联免疫(ELISA)方法,检测99例长期服用抗精神病药治疗的慢性精神分裂症患者(精神分裂症组)和83名健康对照(对照组)血清S100B蛋白浓度,比较2组间差异。采用阳性和阴性症状量表(Positive and Negative Syndrome Scale,PANSS)评定精神病理症状,分析血清S100B蛋白浓度与PANSS评分及其疾病状况间的关系。结果:①精神分裂症组血清S100B浓度高于对照组[(0.158±0.037)μg/Lvs.(0.124±0.055)μg/L,P<0.001];精神分裂症组中,男性患者S100B水平高于女性[(0.169±0.035)μg/Lvs.(0.136±0.030)μg/L,P<0.001],采用典型抗精神病药、非典型抗精神病药、氯氮平和联合治疗4个亚组间差异无统计学意义(F=1.22,P=0.307);②精神分裂症患者血清S100B浓度与PANSS阴性症状分(r=-0.31,P=0.002)、反应缺乏因子(r=-0.24,P=0.017)负相关。结论:血清S100B水平在慢性精神分裂症患者中显著升高;S100B对疾病的进程可能有一定的保护作用。Objective： To investigate the correlation of the serum S100B protein levels with psychopathologi- cal symptoms in the long-term antipsychotic-medication chronic patients with schizophrenia. Methods： The serum S100B protein levels in 99 cases of the long-term antipsychotic-medication patients with chronic schizophrenia （ schizophrenic group ） and 83 healthy volunteers （ control group } were examined by enzyme-linked immuno-sorbent assay （ELSIA ） . The serum S100B levels were compared between the schizophrenics and con- trois. Psychopathological symptoms were assessed with the Positive and Negative Symptom Scale （ PANSS ） . The relationship of the serum S100B levels and the PANSS scores were analyzed in schizophrenic group. Results： { 1 ） The serum S100B levels in schizophrenic group were significantly higher than that in control group [ （0. 158 ± 0. 037 ] μg/L vs. （ 0. 124 ±0. 055 ] μg/L, P 〈 0. 001 ] . The serum S100B levels in male patients were markedly higher than that in females [ （0. 169 ±0.035） μg/L vs. [0. 136 ±0.030]μg/L, P〈0.001], but significant differences were not found among antipsychotic-medicafion subgroups （ F = 1.22, P = 0. 307 ）. （ 2 ） The serum S100B levels were significantly correlated with negative sub-score （ r = -0. 31, P = 0. 002） and response eficiency factor （r = -0. 24, P =0. 017 ） of the PANSS. Conclusion： The serum S100B protein levels increase and may provide potential protecting for development of disease in long-term antipsyehotic-medication chronic patients with schizophrenia.

关 键 词：精神分裂症 SIOOB蛋白 抗精神病药物 病例对照研究 

分 类 号：R749.3[医药卫生—神经病学与精神病学] R749.053[医药卫生—临床医学]